Evaluation of efficacy of QR678
QR678
QR678 Neo; hair growth
chemotherapy-induced alopecia
hair loss
Journal
Journal of cosmetic dermatology
ISSN: 1473-2165
Titre abrégé: J Cosmet Dermatol
Pays: England
ID NLM: 101130964
Informations de publication
Date de publication:
Dec 2020
Dec 2020
Historique:
received:
19
08
2020
revised:
21
09
2020
accepted:
23
09
2020
pubmed:
6
10
2020
medline:
15
5
2021
entrez:
5
10
2020
Statut:
ppublish
Résumé
Cancers are one of the main reasons of morbidity and mortality globally. Chemotherapy-induced alopecia (CIA) is one of the most alarming, terrifying, and traumatic adverse effects. A range of therapeutic measures has been suggested to alleviate CIA, but at present, there is no accepted pharmacological therapy that can assure prevention or management. The aim of the present study was to evaluate the efficacy of QR 678 Neo® therapy in the treatment of persistent chemotherapy-induced alopecia in women and men treated with cytotoxic chemotherapy for breast and lung cancers, respectively. A total of 8 male patients with history of lung cancer and 12 female patients with history of breast cancer in the age range of 25-60 years, with WHO classification of grade I and II persistent alopecia who had undergone chemotherapy treatment, were selected for the study. At each visit, 1.5 mL solution of QR 678 Marked improvement was seen in the global assessment score at 6 months (mean-8) which was maintained even after 1 year. Mean score increase in hair count at 6 months was 12.71 which further increased at 1 year. High satisfaction score was given by patients for slowing of hair loss (mean = 4.2) and also for overall hair growth. For appearance and growth of hair, the mean value was 3.4 and 3.8, respectively. The formulation of QR 678
Sections du résumé
BACKGROUND
BACKGROUND
Cancers are one of the main reasons of morbidity and mortality globally. Chemotherapy-induced alopecia (CIA) is one of the most alarming, terrifying, and traumatic adverse effects. A range of therapeutic measures has been suggested to alleviate CIA, but at present, there is no accepted pharmacological therapy that can assure prevention or management.
AIM
OBJECTIVE
The aim of the present study was to evaluate the efficacy of QR 678 Neo® therapy in the treatment of persistent chemotherapy-induced alopecia in women and men treated with cytotoxic chemotherapy for breast and lung cancers, respectively.
METHODS
METHODS
A total of 8 male patients with history of lung cancer and 12 female patients with history of breast cancer in the age range of 25-60 years, with WHO classification of grade I and II persistent alopecia who had undergone chemotherapy treatment, were selected for the study. At each visit, 1.5 mL solution of QR 678
RESULTS
RESULTS
Marked improvement was seen in the global assessment score at 6 months (mean-8) which was maintained even after 1 year. Mean score increase in hair count at 6 months was 12.71 which further increased at 1 year. High satisfaction score was given by patients for slowing of hair loss (mean = 4.2) and also for overall hair growth. For appearance and growth of hair, the mean value was 3.4 and 3.8, respectively.
CONCLUSION
CONCLUSIONS
The formulation of QR 678
Substances chimiques
Antineoplastic Agents
0
Intercellular Signaling Peptides and Proteins
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
3270-3279Informations de copyright
© 2020 Wiley Periodicals LLC.
Références
Wils R, Jacob AR, Daniel ES, Chacko RT, Reka S. Distress and coping in cancer patients experiencing chemotherapy-induced alopecia. Indian J Cont Nurs Educ. 2019;20:60-64.
Choi EK, Kim I-R, Chang O, et al. Impact of chemotherapy-induced alopecia distress on body image, psychosocial well-being, and depression in breast cancer patients. Psycho Oncol. 2014;23(10):1103-1110.
Moreira H, Canavarro MC. The association between self-consciousness about appearance and psychological adjustment among newly diagnosed breast cancer patients and survivors: the moderating role of appearance investment. Body Image. 2012;9(2):209-215.
Kennedy F, Harcourt D, Rumsey N, White P. The psychosocial impact of ductal carcinoma in situ (DCIS): a longitudinal prospective study. Breast. 2010;19:382-387.
Reich M, Lesur A, Perdrizet-Chevallier C. Depression, quality of life and breast cancer: a review of the literature. Breast Cancer Res Treat. 2008;110:9-17.
Trueb RM. Chemotherapy-induced hair loss. Skin Therapy Lett. 2010;15:5-7.
Rossi A, Fortuna MC, Caro G, et al. Chemotherapy-induced alopecia management: Clinical experience and practical advice. J CosmetDermatol. 2017;1-5.
Chiewchanvit S, Noppakun K, Kanchanarattanakorn K. Mucocutaneous adverse effects of chemotherapy in 74 patients from MaharajNakornChianag Mai hospital. J Med Assoc Thai. 2004;87:508-514.
Rosman S. Cancer and stigma: experience of patients with chemotherapy-induced alopecia. Patient Educ Couns. 2004;52:333-339.
Richer MC, Ezer H. Living in it, living with it, and moving on: dimensions of meaning during chemotherapy. Oncol Nurs Forum. 2002;29:113-119.
Browall M, Gaston-Johansson F, Danielson E. Postmenopausal women with breast cancer: their experiences of the chemotherapy treatment period. Cancer Nurs. 2006;29:34-42.
Boehmke MM, Dickerson SS. Symptom, symptom experiences, and symptom distress encountered by women with breast cancer undergoing current treatment modalities. Cancer Nurs. 2005;28:382-389.
Hesketh PJ, Batchelor D, Golant M, Lyman GH, Rhodes N, Yardley D. Chemotherapy-induced alopecia: psychosocial impact and therapeutic approaches. Support Care Cancer. 2004;12:543-549.
Pallandino Green S, Pritchard ME. Predictors of body image dissatisfaction in adult men and women. Soc Behav Personal. 2003;31:215-222.
Lemieux J, Maunsell E, Provencher L. Chemotherapy-induced alopecia and effects on quality of life among women with breast cancer: a literature review. Psycho-Oncology. 2008;17(4):317-328.
Coates A, Abraham S, Kaye SB, et al. On the receiving end-patient perception of the side-effects of cancer chemotherapy. Eur J Cancer ClinOncol. 1983;19(2):203-208.
Carelle N, Piotto E, Bellanger A, Germanaud J, Thuillier A, Khayat D. Changing patient perceptions of the side effects of cancer chemotherapy. Cancer. 2002;95(1):155-163.
Kiebert GM, de Haes JHCJM, Kievit J, van de Velde CJH. Effect of peri-operative chemotherapy on the quality of life of patients with early breast cancer. Eur J Cancer. 1990;26(10):1038-1042.
Sitzia J, Huggins L. Side effects of cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) chemotherapy for breast cancer. Cancer Pract. 1998;6(1):13-21.
Duric VM. Patients’ preferences for adjuvant chemotherapy in early breast cancer: what makes AC and CMF worthwhile now? Ann Oncol. 2005;16(11):1786-1794.
Freedman TG. Social and cultural dimensions of hair loss in women treated for breast cancer. Cancer Nurs. 1994;17:334-341.
van den Hurk CJ, van den Akker-van Marle ME, Breed WP, van de Poll-Franse LV, Nortier JW, Coebergh JW. Impact of scalp cooling on chemotherapy-induced alopecia, wig use and hair growth of patients with cancer. Eur J Oncol Nurs. 2013;17:536-540.
Borsellino M, Young MM. Anticipatory coping. Clin J Oncol Nurs. 2011;15(3):311-315.
Jayde V, Boughton M, Blomfield P. The experience of chemotherapy-induced alopecia for Australian women with ovarian cancer. Eur J Cancer Care. 2013;22(4):503-512.
Can G, Demir M, Erol O, Aydiner A. A comparison of men and women’s experiences of chemotherapy-induced alopecia. Eur J Oncol Nurs. 2013;17(3):255-260.
Amiel P, Dauchy S, Bodin J, et al. Evaluating beauty care provided by the hospital to women suffering from breast cancer: qualitative aspects. Support Care Cancer. 2009;17(7):839-845.
Oncoline. Guideline Mamma Carcinoma 2012 (RichtlijnMammacarcinoom 2012). Comprehensive Cancer Centre, The Netherlands, Utrecht. www.oncoline.nl/mammacarcinoom 2012.
Lemieux J, Amireault C, Provencher L, Maunsell E. Incidence of scalp metastases in breast cancer: A retrospective cohort study in women who were offered scalp cooling. Breast Cancer Res Treat. 2009;118:547-552.
Lindley C, McCune JS, Thomason TE, et al. Perception of chemotherapy side effects cancer versus noncancer patients. Cancer Pract. 1999;7(2):59-65.
Kapoor R, Shome D. Intradermal injections of a hair growth factor formulation for enhancement of human hair regrowth - safety and efficacy evaluation in a first-in-man pilot clinical study. J Cosmet Laser Ther. 2018;20:369-379.
Kapoor R, Shome D, Vadera S. QR 678 hair growth factors formulation - In vivo cellular toxicity & In vivo animal efficacy study. Plast Reconstr Surg Open. 2020;8.
Villasante AC, Herskovitz I, Mauro LM, Jimenez JJ. Chemotherapy-induced alopecia. J Clin Investig Dermatol. 2014;2(2):8.
Chon SY, Champion RW, Geddes ER, Rashid RM. Chemotherapy-induced alopecia. J Am Acad Dermatol. 2012;67(1):37-47.
van den Hurk CJG, Mols F, Vingerhoets AJJM, Breed WPM. Impact of alopecia and scalp cooling on the well-being of breast cancer patients. Psycho Oncol. 2010;19:701-709.
Frith H, Harcourt D, Fussell A. Anticipating an altered appearance: women undergoing chemotherapy treatment for breast cancer. Eur J Oncol Nurs. 2007;11:385-391.
Tighe M, Molassiotis A, Morris J, Richardson J. Coping, meaning and symptom experience: a narrative approach to the over whelming impacts of breast cancer in the first year following diagnosis. Eur J Oncol Nurs. 2011;15:226-232.
Saraswat N, Chopra A, Sood A, Kamboj P, Kumar S. A descriptive study to analyze chemotherapy-induced hair loss and its psychosocial impact in adults: Our experience from a tertiary care hospital. Indian Dermatol Online J. 2019;10:426-430.
Yeager CE, Olsen EA. Treatment of chemotherapy-induced alopecia. Dermatol Ther. 2011;24:432-442.
Luoma M-L, Hakamies-Blomqvist L. The meaning of quality of life in patients being treated for advanced breast cancer: a qualitative study. Psycho Oncol. 2004;13:729-739.
Macquart-Moulin G, Viens P, Palangié T, et al. High-dose sequential chemotherapy with recombinant granulocyte colony-stimulating factor and repeated stem-cell support for inflammatory breast cancer patients: Does impact on quality of life jeopardize feasibility and acceptability of treatment? J Clin Oncol. 2000;18:754-764.
Moreira H, Silva S, Canavarro MC. The role of appearance investment in the adjustment of women with breast cancer. Psycho Oncol. 2010;19(9):959-966.
Brunet J, Sabiston CM, Burke S. Surviving breast cancer: women’s experiences with their changed bodies. Body Image. 2013;10(3):344-351.
Olsen EA. Chemotherapy-induced alopecia: overview and methodology for characterizing hair changes and regrowth. In: Oliver IN, ed. The MASCC textbook of cancer supportive care and survivorship. New York, NY: Springer; 2011:381-388.
Simister JM. Letter: alopecia and cytotoxic drugs. Br Med J. 1966;2(5522):1138.
Sredni B, Xu RH, Albeck M, et al. The protective role of the immune modulator AS101 against chemotherapy-induced alopecia studies on human and animal models. Int J Cancer. 1996;65(1):97-103.
Sredni B, Caspi RR, Klein A, et al. A new immune modulating compound (AS-101) with potential therapeutic application. Nature. 1987;330(6144):173-176.
Sredni B, Albeck M, Tichler T, et al. Bone marrow-sparing and prevention of alopecia by AS101 in non-small-cell lung cancer patients treated with carboplatin and etoposide. J Clin Oncol. 1995;13:2342-2353.
Hidalgo M, Rinaldi D, Medina G, et al. A phase I trial of topical topitriol (calcitriol, 1,25-dihydroxyvitamin D3) to prevent chemotherapy-induced alopecia. Anticancer Drugs. 1999;10:393-395.
Wat H, Dytoc M. Off-label uses of topical vitamin d in dermatology: a systematic review. J Cutan Med Surg. 2014;18:91-108.
Bleiker TO, Nicolaou N, Traulsen J, Hutchinson PE. ‘Atrophic telogen effluvium’ from cytotoxic drugs and a randomized controlled trial to investigate the possible protective effect of pretreatment with a topical vitamin D3 analogue in humans. Br J Dermatol. 2005;153:103-112.
Auvinen PK, Mähönen UA, Soininen KM, et al. The effectiveness of a scalp cooling cap in preventing chemotherapy-induced alopecia. Tumori. 2010;96:271-275.
Lemieux J, Provencher L, Perron L, et al. No effect of scalp cooling on survival among women with breast cancer. Breast Cancer Res Treat. 2015;149:263-268.
Betticher DC, Delmore G, Breitenstein U, et al. Efficacy and tolerability of two scalp cooling systems for the prevention of alopecia associated with docetaxel treatment. Supportive Care Cancer. 2013;21:2565-2573.
Kruse M, Abraham J. Management of chemotherapy induced alopecia with scalp cooling. Am Soc Clin Oncol. 2018;14:3.
Duvic M, Lemak NA, Valero V, et al. A randomized trial of minoxidil in chemotherapy-induced alopecia. J Am Acad Dermatol. 1996;35:74-78.
Rodriguez R, Machiavelli M, Leone B, et al. Minoxidil (Mx) as a prophylaxis of doxorubicin-induced alopecia. Ann Oncol. 1994;5:769-770.